Efficy Revenue and Competitors

BE

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Efficy's estimated annual revenue is currently $31.7M per year.(i)
  • Efficy's estimated revenue per employee is $159,500
  • Efficy's pricing is $780 per year.

Employee Data

  • Efficy has 199 Employees.(i)
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$17.3M119-7%N/AN/A
#2
$3.7M21N/AN/AN/A
#3
$4M3831%$1.9MN/A
#4
$24.6M154N/AN/AN/A
#5
$19.5M13930%€3MN/A
#6
$1M12N/AN/AN/A
#7
$0.4M6N/AN/AN/A
#8
$1M12N/AN/AN/A
#9
$2.1M21N/AN/AN/A
#10
$0.7M9N/AN/AN/A
#11
$0.7M9N/AN/AN/A
#12
$0.6M8N/AN/AN/A
#13
$7.9M63N/AN/AN/A
#14
$17.8M123N/AN/AN/A
#15
$2M20N/AN/AN/A
#16
$7.2M36N/AN/AN/A
#17
$26M173-6%$88.6MN/A
#18
$3.5M30N/AN/AN/A
#19
$1.1M13N/AN/AN/A
#20
$1M12N/AN/AN/A
Add Company

keywords:saas

N/A

Total Funding

199

Number of Employees

$31.7M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Efficy's People

NameTitleEmail/Phone
1
Team lead local marketing managersReveal Email/Phone
2
Sales Development RepresentativeReveal Email/Phone
3
Team Leader & Project DirectorReveal Email/Phone
4
Marketing Operations ManagerReveal Email/Phone
5
Digital MarketerReveal Email/Phone
6
Head Customer SuccessReveal Email/Phone

Efficy News

2022-03-22 - Clinical practice guideline for transurethral plasmakinetic ...

Efficy and safety of transurethral plasmakinetic resection of prostate versus transurethral plasmakinetic enucleation of prostate in...

2021-02-17 - Belgian CRM company Efficy acquires Denmark’s webCRM to expand into Nordics

Efficy, a European CRM specialist, has acquired webCRM, a Danish solution for small- and mid-sized customers. With this acquisition, the Belgian company enters the Scandinavian market in pursuit of its goal to capture 5 percent of the European CRM market by 2024. Founded back in 2005, Efficy ha ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$46M1998%N/A
#2
$48.6M19921%$213M
#3
$15M19911%N/A
#4
$15M1998%N/A
#5
$46M199-8%N/A